[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600228":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":23,"centralContacts":26,"locations":32,"responsibleParty":48,"collaborators":23,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":23,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":23,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":35,"whyStopped":23,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"The First Affiliated Hospital of University of Science and Technology of China","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"standard medical management","ACTIVE_COMPARATOR",[12],"Drug: standard medical management",{"label":14,"type":15,"description":16,"interventionNames":17},"TNK plus standard medical treatment","EXPERIMENTAL","Patients in the TNK treatment group will receive TNK intravenous thrombolysis and the usual dosage for TNK intravenous thrombolysis is 0.25mg\u002FKg, with a maximum of 25mg.",[18],"Drug: TNK plus standard medical treatment",[20,24],{"type":21,"name":14,"description":16,"armGroupLabels":22,"otherNames":23},"DRUG",[14],null,{"type":21,"name":9,"description":9,"armGroupLabels":25,"otherNames":23},[9],[27],{"name":28,"role":29,"phone":30,"phoneExt":23,"email":31},"Wei Hu MD,PhD","CONTACT","+86055162284313","andinghu@ustc.edu.cn",[33],{"facility":34,"status":35,"city":36,"state":23,"zip":23,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"The First Affiliated Hospital of the University of Science and Technology of China","RECRUITING","Hefei","China","CN",{"type":40,"coordinates":41},"Point",[42,43],117.28083,31.86389,{"lat":43,"lon":42},[46,47],{"name":28,"role":29,"phone":30,"phoneExt":23,"email":31},{"name":23,"role":29,"phone":23,"phoneExt":23,"email":31},{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"PRINCIPAL_INVESTIGATOR","Wei Hu","Professor","100600228","efficacy-and-safety-of-tenecteplase-intravenous-thrombolysis-in-acute-posterior-circulation-ischemic-stroke-within-45-24-hours-after-onset-100600228",false,"NCT07094763","Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset","Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset: A Multicenter, Prospective, Randomized, Open-Label, Blinded Endpoint Trial","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Meeting at least one of the following criteria: acute posterior circulation ischemic stroke confirmed by MRI; symptomatic stenosis or occlusion of a posterior circulation large vessel on vascular imaging (CTA\u002FMRA\u002FDSA); perfusion imaging demonstrating clinically relevant hypoperfusion in the posterior circulation territory.\n3. Onset time between 4.5-24 hours (for wake-up stroke or unwitnessed stroke, onset time is defined as the midpoint between last known well and symptom detection).\n4. NIHSS score\\>3.\n5. PC-ASPECTS ≥7 (if discrepancy exists between DWI and CT findings, CT assessment takes precedence).\n6. Pre-stroke mRS ≤1.\n7. Signed informed consent by the patient or legally authorized representative.\n\nExclusion Criteria:\n\n1. Contraindication to tenecteplase or its components.\n2. Planing to receive endovascular therapy with thrombectomy, angioplasty or stenting whin 3 months.\n3. Acute anterior circulation infarction confirmed by MRI, anterior circulation large vessel occlusion on vascular imaging (CTA\u002FMRA\u002FDSA), or anterior circulation hypoperfusion on perfusion imaging.\n4. History of intracranial hemorrhage.\n5. Stroke, myocardial infarction, severe traumatic brain injury, or intracranial\u002Fspinal surgery within the preceding 3 months.\n6. Intracranial tumor, arteriovenous malformation (AVM), or giant aneurysm.\n7. Active internal bleeding, major surgery, trauma, gastrointestinal\u002Furinary tract bleeding within 3 weeks.\n8. Non-compressible arterial puncture within 1 week.\n9. Suspected aortic dissection.\n10. Clinically significant bleeding or coagulopathy, including: Warfarin use with INR \\>1.7 or PT \\>15 s; Low-molecular-weight heparin within 24 hours; Direct oral anticoagulants within 48 hours; Laboratory abnormalities (e.g., APTT \\>40 s).\n11. Platelet dysfunction or platelet count \\\u003C100×10⁹\u002FL.\n12. Uncontrolled hypertension (systolic BP \\>180 mmHg or diastolic BP \\>110 mmHg unresponsive to antihypertensive therapy).\n13. Uncontrolled hypoglycemia\u002Fhyperglycemia (\\\u003C50 mg\u002FdL \\[2.8 mmol\u002FL\\] or \\>400 mg\u002FdL \\[22.2 mmol\u002FL\\]).\n14. Pregnancy or lactation.\n15. A life expectancy of less than three months.\n16. Participation in other clinical trials within 3 months or ongoing trial enrollment.\n17. Inability to follow up (e.g., no fixed residence, overseas patients).\n18. Patient deemed unsuitable for the trial by site investigator.","ALL","18 Years","100 Years",{"count":63,"type":64},406,"ESTIMATED","INTERVENTIONAL",[67],"NA","This study aims to evaluate the efficacy and safety of tenecteplase (TNK) intravenous thrombolysis within the extended time window (4.5 to 24 hours) in patients with acute posterior circulation ischemic stroke.",[70],"Acute Ischemic Stroke",[72,73,74,75],"TNK Intravenous Thrombolysis","Acute ischemic stroke","posterior circulation","Beyond optimal time window","2026-06-05",{"date":78,"type":79},"2026-06-08","ACTUAL",{"date":81,"type":79},"2025-11-05",{"date":83,"type":64},"2027-12-30",{"name":5,"class":6},1]